This question set covers two of the four cornerstone drug classes in hypertension management — calcium channel blockers (CCBs) and diuretics. Together with the ACE inhibitors and ARBs from earlier modules, these four classes form the evidence-based foundation used in the vast majority of hypertensive patients worldwide. CCBs divide into two pharmacologically distinct subclasses with very different clinical profiles; diuretics divide into three mechanistically distinct classes with different sites of action, potency, and adverse effect profiles. Getting these distinctions right is not a memorization exercise — it is the foundation of rational prescribing across dozens of clinical scenarios you will encounter repeatedly in practice. Some questions here are straightforward classification and mechanism questions you should get right if you have done the reading. Others ask you to connect a mechanism to a clinical consequence, which requires more thought. Read every rationale carefully, including for questions you answer correctly — the reasoning embedded in the rationale is what the higher tiers will ask you to apply fluently.
1. Calcium channel blockers (CCBs) exert their primary antihypertensive effect by blocking a specific type of ion channel in vascular smooth muscle. Which channel subtype is the primary pharmacological target shared by all clinically used CCBs?
A) Voltage-gated L-type (long-lasting) calcium channels in vascular smooth muscle
B) Receptor-operated calcium channels activated by angiotensin II binding
C) T-type calcium channels in the sinoatrial node
D) Voltage-gated sodium channels in vascular smooth muscle
E) ATP-sensitive potassium channels in vascular endothelium
ANSWER: A
Rationale:
All clinically used CCBs target voltage-gated L-type calcium channels, which are the principal pathway for calcium entry that triggers contraction in vascular smooth muscle. Blocking these channels reduces intracellular calcium, causing smooth muscle relaxation, arteriolar dilation, and a fall in total peripheral resistance — the central antihypertensive mechanism of the entire class.
Option B: Option B is incorrect because receptor-operated channels are activated by ligands such as angiotensin II and are not the primary pharmacological target of therapeutic CCBs.
Option C: Option C is incorrect because T-type channels contribute to sinoatrial node automaticity but are not the target of clinically used antihypertensive CCBs.
Option D: Option D is incorrect because voltage-gated sodium channels are the target of class I antiarrhythmics and local anesthetics, not CCBs.
Option E: Option E is incorrect because ATP-sensitive potassium channels are the target of potassium channel openers such as minoxidil, not calcium channel blockers.
2. The CCB class divides into two pharmacologically distinct subclasses. Which of the following correctly identifies the fundamental difference between dihydropyridine CCBs (such as amlodipine) and non-dihydropyridine CCBs (such as verapamil and diltiazem)?
A) Dihydropyridines block T-type channels; non-dihydropyridines block L-type channels
B) Dihydropyridines are renally eliminated; non-dihydropyridines undergo hepatic metabolism via CYP3A4
C) Dihydropyridines have high vascular selectivity with minimal cardiac effects at therapeutic doses; non-dihydropyridines act on both vascular smooth muscle and cardiac tissue, producing negative chronotropy and negative dromotropy in addition to vasodilation
D) Non-dihydropyridines cause more peripheral edema than dihydropyridines due to greater arteriolar dilation
E) Dihydropyridines are contraindicated in coronary artery disease; non-dihydropyridines are preferred for all patients with angina
ANSWER: C
Rationale:
The fundamental distinction between the two CCB subclasses is tissue selectivity. Dihydropyridines (amlodipine, nifedipine, felodipine) bind preferentially to vascular L-type channels and have minimal direct cardiac effects at therapeutic doses — no clinically meaningful slowing of heart rate or AV conduction. Non-dihydropyridines (verapamil, diltiazem) act on both vascular and cardiac tissue, producing significant negative chronotropy (reduced sinus rate) and negative dromotropy (slowed AV conduction) in addition to vasodilation. This cardiac tissue effect is what makes non-DHP CCBs useful for rate control in atrial fibrillation — and what makes them dangerous in combination with beta-blockers or in heart failure with reduced ejection fraction.
Option A: Option A is incorrect because both subclasses target L-type channels.
Option B: Option B is incorrect because both subclasses undergo hepatic CYP3A4 metabolism.
Option D: Option D is incorrect because peripheral edema is a dihydropyridine adverse effect from preferential arteriolar dilation, not a non-DHP feature.
Option E: Option E is incorrect because DHP CCBs including amlodipine are used in stable coronary artery disease.
3. Amlodipine is the most widely prescribed CCB worldwide. Which pharmacokinetic property is primarily responsible for its suitability for once-daily dosing and its low rate of reflex tachycardia compared to older calcium channel blockers?
A) Amlodipine is a prodrug converted slowly to its active form over 24 hours, providing a controlled-release effect
B) Amlodipine has a half-life of 35–50 hours — the longest among all CCBs — providing smooth, gradual onset and sustained 24-hour blood pressure coverage from a single daily dose
C) Amlodipine is eliminated entirely by the kidneys, giving it a predictable duration independent of hepatic function
D) Amlodipine undergoes zero-order kinetics, maintaining a perfectly flat plasma concentration throughout the dosing interval
E) Amlodipine selectively binds to inactivated L-type channels, prolonging its duration of action without requiring high peak plasma concentrations
ANSWER: B
Rationale:
Amlodipine's half-life of 35–50 hours is the longest among clinically used CCBs and is the pharmacokinetic basis for both its once-daily dosing and its low rate of reflex tachycardia. The slow rise in plasma concentration after each dose produces gradual vasodilation rather than abrupt arteriolar dilation, minimizing the reflex sympathetic activation that caused cardiovascular harm with immediate-release nifedipine. A single daily dose maintains therapeutic concentrations continuously across the 24-hour period, including the critical early morning hours when cardiovascular events peak.
Option A: Option A is incorrect because amlodipine is not a prodrug — it is pharmacologically active as administered.
Option C: Option C is incorrect because amlodipine undergoes hepatic metabolism via CYP3A4; no dose adjustment is required in renal impairment but caution is warranted in severe hepatic impairment.
Option D: Option D is incorrect because amlodipine follows first-order kinetics; zero-order kinetics describes drugs like ethanol and phenytoin at toxic concentrations.
Option E: Option E is incorrect because while DHP CCBs do preferentially bind inactivated channel states, this property explains vascular selectivity, not the long duration of action — the half-life is the pharmacokinetic basis for duration.
4. A 71-year-old man with hypertension and permanent atrial fibrillation (AF) needs both blood pressure control and ventricular rate control. He is not on a beta-blocker. Which subclass of CCB is most appropriate, and what property makes it suitable for rate control in AF?
A) A dihydropyridine CCB such as amlodipine — it has the most potent antihypertensive effect and indirectly reduces the ventricular rate by lowering blood pressure
B) A dihydropyridine CCB such as nifedipine — its rapid onset makes it ideal for acute rate control in atrial fibrillation
C) Either subclass is equally appropriate — all CCBs slow AV nodal conduction as part of their shared mechanism
D) A non-dihydropyridine CCB such as verapamil or diltiazem — their negative dromotropic effect (slowing of AV nodal conduction) controls the ventricular rate in AF while also lowering blood pressure through vasodilation
E) A non-dihydropyridine CCB such as verapamil or diltiazem — because they cause reflex tachycardia, which paradoxically resets the AF rate to a more manageable ventricular response
ANSWER: D
Rationale:
Non-dihydropyridine CCBs (verapamil and diltiazem) act on both vascular smooth muscle and cardiac tissue. Their negative dromotropic effect — direct slowing of conduction through the AV node via L-type calcium channel blockade in nodal cells — controls the ventricular rate in atrial fibrillation by limiting how many atrial impulses are conducted to the ventricles. This dual action (vasodilation for blood pressure plus AV nodal slowing for rate control) makes them the CCB subclass of choice when both goals are needed simultaneously.
Option A: Option A is incorrect because dihydropyridines such as amlodipine have no clinically meaningful effect on AV nodal conduction and do not control the ventricular rate in AF.
Option B: Option B is incorrect for the same reason, and rapid-onset DHP CCBs are generally avoided due to reflex tachycardia risk.
Option C: Option C is incorrect because AV nodal slowing is specific to non-DHP CCBs, not a property shared by all CCBs.
Option E: Option E is incorrect because non-DHP CCBs do not cause reflex tachycardia — their cardiac rate-slowing effect offsets the vasodilatory reflex.
5. A 60-year-old man on amlodipine 10 mg daily develops bilateral ankle swelling three months after starting the drug. His BNP is normal and there is no evidence of heart failure or deep vein thrombosis. Which of the following best describes the mechanism of this edema?
A) Amlodipine activates the renin-angiotensin-aldosterone system, causing sodium and water retention that pools in dependent tissues
B) Amlodipine causes lymphatic obstruction in the lower extremities through a direct toxic effect on lymphatic endothelium
C) Amlodipine causes hypoalbuminemia by reducing hepatic protein synthesis, lowering plasma oncotic pressure
D) Amlodipine causes preferential dilation of arterioles without a matched increase in venodilation, raising capillary hydrostatic pressure in dependent tissues and driving fluid into the interstitium
E) Amlodipine causes a histamine-mediated local inflammatory reaction in dependent tissues that produces pitting edema
ANSWER: D
Rationale:
CCB-associated peripheral edema results from the hemodynamic imbalance created by preferential arteriolar dilation. Amlodipine dilates resistance arterioles more than venous capacitance vessels. The resulting increase in capillary hydrostatic pressure — the force driving fluid out of the capillary into surrounding tissue — is not offset by a compensatory rise in venous pressure to draw fluid back. Fluid accumulates in the interstitium of dependent tissues, producing pitting edema. This mechanism is critically distinct from sodium-mediated volume overload, which is why diuretics have limited efficacy for CCB-associated edema — there is no excess sodium to excrete. The edema is dose-dependent and affects up to 10–30% of patients on amlodipine 10 mg daily.
Option A: Option A is incorrect because while RAAS activation is a compensatory response to vasodilation, it is not the direct cause of the capillary-level fluid shift producing edema.
Option B: Option B is incorrect because lymphatic obstruction is not the mechanism.
Option C: Option C is incorrect because amlodipine does not cause hypoalbuminemia.
Option E: Option E is incorrect because the edema is hemodynamic, not inflammatory or allergic.
6. Short-acting (immediate-release) nifedipine is contraindicated for the treatment of chronic hypertension, while long-acting formulations (GITS, XL) are acceptable. Which of the following best explains this distinction?
A) Immediate-release nifedipine produces a rapid plasma concentration peak causing abrupt intense vasodilation, triggering a powerful reflex sympathetic surge with tachycardia and elevated catecholamines — associated with increased rates of adverse cardiovascular events; long-acting formulations release nifedipine gradually, avoiding this reflex
B) Immediate-release nifedipine is absorbed sublingually and reaches toxic CNS concentrations, causing neurological adverse effects not seen with oral long-acting formulations
C) Immediate-release nifedipine irreversibly blocks L-type calcium channels; long-acting formulations produce reversible competitive blockade
D) Immediate-release nifedipine blocks both L-type and T-type channels; long-acting formulations are selective for L-type channels only
E) Immediate-release nifedipine causes rebound hypertension upon discontinuation due to receptor upregulation; long-acting formulations taper plasma levels gradually, avoiding this rebound
ANSWER: A
Rationale:
The pharmacokinetic profile of the formulation — not the drug itself — determines the safety difference between immediate-release and long-acting nifedipine. Immediate-release nifedipine produces a rapid, steep rise in plasma concentration, causing abrupt and intense arteriolar vasodilation. The sudden fall in blood pressure triggers a powerful reflex sympathetic response: tachycardia, increased myocardial oxygen demand, catecholamine surge, and platelet activation — all of which increase the risk of adverse cardiovascular events including myocardial infarction. Long-acting formulations (GITS, XL, CC) release nifedipine continuously over 24 hours, maintaining therapeutic plasma levels without the concentration peak. The drug itself is pharmacologically identical in both formulations.
Option B: Option B is incorrect because nifedipine is not administered sublingually in clinical practice and CNS toxicity is not the mechanism of cardiovascular harm.
Option C: Option C is incorrect because nifedipine's L-type channel blockade is competitive and reversible in both formulations.
Option D: Option D is incorrect because both formulations are dihydropyridines acting on L-type channels; neither blocks T-type channels clinically.
Option E: Option E is incorrect because rebound hypertension on discontinuation is a feature of centrally acting sympatholytics such as clonidine, not calcium channel blockers.
7. Verapamil is the most cardiac-selective non-dihydropyridine CCB. Which of the following adverse effects is most characteristic of verapamil and is caused by calcium channel blockade in intestinal smooth muscle rather than vascular or cardiac tissue?
A) Peripheral edema — from arteriolar dilation in the lower extremities
B) Gingival hyperplasia — from calcium channel blockade in gingival fibroblasts
C) Constipation — occurring in up to 25% of patients due to reduced intestinal smooth muscle peristalsis from L-type calcium channel blockade in the gut
D) Diarrhea — from increased intestinal fluid secretion secondary to calcium channel inhibition in enterocytes
E) Hepatotoxicity — from accumulation of verapamil's active metabolite norverapamil in hepatocytes
ANSWER: C
Rationale:
Constipation is the most common adverse effect of verapamil, occurring in up to 25% of patients. L-type calcium channels are present in intestinal smooth muscle and regulate peristaltic contractions. Verapamil's blockade of these channels reduces intestinal motility, slowing transit and causing constipation — the same calcium channel mechanism responsible for its vascular and cardiac effects operating in a different tissue. This adverse effect is clinically important because it can significantly affect quality of life and adherence, and because it is mechanistically predictable (not idiosyncratic).
Option A: Option A is incorrect because peripheral edema is a dihydropyridine adverse effect from arteriolar dilation — verapamil's cardiac effects offset vasodilatory reflex and it causes less peripheral edema than DHP CCBs.
Option B: Option B is incorrect because gingival hyperplasia is a CCB class effect most commonly associated with nifedipine, not specifically verapamil, and its mechanism involves gingival fibroblast proliferation rather than direct calcium channel effects.
Option D: Option D is incorrect because verapamil reduces, not increases, intestinal motility.
Option E: Option E is incorrect because while verapamil does produce an active metabolite (norverapamil) and undergoes extensive hepatic metabolism, hepatotoxicity is not a characteristic adverse effect.
8. Thiazide and thiazide-like diuretics lower blood pressure through two temporally distinct mechanisms. Which of the following correctly identifies the sequence of these mechanisms?
A) Acutely: direct arteriolar vasodilation reduces peripheral resistance; chronically: sodium excretion is maintained indefinitely, preventing volume re-expansion
B) Acutely: natriuresis reduces plasma volume and cardiac output; chronically: plasma volume largely normalizes but a persistent reduction in total peripheral resistance maintains the antihypertensive effect through mechanisms that are not fully understood
C) Acutely: renin suppression reduces angiotensin II formation; chronically: aldosterone inhibition prevents potassium loss and sustains volume depletion
E) Acutely and chronically: the mechanism is identical — continuous natriuresis and volume depletion sustained throughout the full duration of treatment
ANSWER: B
Rationale:
Thiazide diuretics produce blood pressure reduction through a well-characterized two-phase mechanism. In the first days to weeks, natriuresis (sodium and water excretion) reduces plasma volume and cardiac output — the acute antihypertensive mechanism. Over weeks to months, plasma volume and cardiac output largely return toward baseline as compensatory mechanisms adjust. Yet blood pressure remains lower. This sustained effect is explained by a persistent fall in total peripheral resistance — the mechanism of which is incompletely understood but may involve reduced vascular smooth muscle sodium content, decreased vascular reactivity to vasoconstrictors, or structural vascular adaptation. This two-phase understanding explains why thiazides remain effective long-term despite their acute volume effects normalizing.
Option A: Option A is incorrect because thiazides do not cause direct arteriolar vasodilation as the primary acute mechanism.
Option C: Option C is incorrect because thiazides activate rather than suppress the RAAS through volume depletion.
Option D: Option D is incorrect because potassium wasting is an adverse effect, not a mechanism, and NCC inhibition is pharmacological (reversible and drug-dependent), not permanent.
Option E: Option E is incorrect because plasma volume normalization over time is well established — persistent volume depletion is not the chronic antihypertensive mechanism.
9. Thiazide diuretics inhibit the sodium-chloride cotransporter (NCC) in the distal convoluted tubule (DCT). Which of the following electrolyte effects is paradoxical — meaning it is the opposite of what might be expected from a natriuretic agent — and has important clinical applications?
A) Hypokalemia — potassium wasting is paradoxically protective against cardiac arrhythmias in hypertensive patients
B) Hypomagnesemia — magnesium loss is paradoxically beneficial because magnesium excess causes vascular stiffness
C) Hyperuricemia — elevated uric acid paradoxically acts as an antioxidant, reducing cardiovascular oxidative stress
D) Hyponatremia — thiazides paradoxically cause both sodium loss and sodium retention simultaneously in different nephron segments
E) Hypocalciuria — thiazides reduce urinary calcium excretion despite causing natriuresis, because NCC inhibition in the DCT enhances passive calcium reabsorption in that segment; this makes thiazides useful in calcium nephrolithiasis and may protect against osteoporotic fractures
ANSWER: E
Rationale:
Thiazides paradoxically reduce urinary calcium excretion (hypocalciuria) despite being natriuretic agents. When NCC is inhibited, intracellular sodium in DCT tubular cells falls. This lowers the intracellular sodium concentration, which enhances the electrochemical gradient that drives passive calcium entry from the tubular lumen into the cell via apical TRPV5 calcium channels. More calcium is reabsorbed rather than excreted in the urine. The clinical consequence is twofold: thiazides are used therapeutically in patients with calcium oxalate nephrolithiasis (reducing the urinary calcium that promotes stone formation), and they may offer modest protection against osteoporotic fractures by reducing calcium loss. This is the opposite of loop diuretics, which increase urinary calcium excretion (calciuria).
Option A: Option A is incorrect because hypokalemia is genuinely harmful — it increases arrhythmia risk rather than being paradoxically protective.
Option B: Option B is incorrect because hypomagnesemia is an adverse effect without a recognized paradoxical benefit.
Option C: Option C is incorrect because while uric acid does have some antioxidant properties in vitro, thiazide-associated hyperuricemia is not considered paradoxically beneficial and increases gout risk.
Option D: Option D is incorrect because thiazide-associated hyponatremia involves sodium loss combined with impaired free water excretion and ADH-mediated water retention — not simultaneous sodium retention.
10. Chlorthalidone and hydrochlorothiazide (HCTZ) both inhibit the NCC transporter in the distal convoluted tubule, yet current guidelines favor chlorthalidone for hypertension. Which pharmacokinetic difference best explains this preference?
A) Chlorthalidone inhibits a structurally different isoform of NCC, producing greater natriuresis per milligram than HCTZ
B) Chlorthalidone is hepatically metabolized while HCTZ is renally eliminated, making chlorthalidone safer in patients with CKD
C) Chlorthalidone has higher oral bioavailability than HCTZ, requiring lower doses for equivalent blood pressure reduction
D) Chlorthalidone has a half-life of approximately 40–60 hours — far longer than HCTZ's 10–12 hours — and accumulates in red blood cells, providing sustained 24-hour and nocturnal blood pressure coverage that HCTZ cannot match
E) Chlorthalidone causes less hypokalemia than HCTZ at equivalent antihypertensive doses, giving it a superior metabolic safety profile
ANSWER: D
Rationale:
The primary pharmacokinetic distinction between chlorthalidone and HCTZ is half-life. Chlorthalidone's half-life of approximately 40–60 hours — prolonged by its accumulation in red blood cells, which act as a reservoir — provides continuous blood pressure coverage across the full 24-hour dosing interval, including the critical nighttime and early morning hours when cardiovascular events are most frequent. HCTZ's half-life of 10–12 hours means plasma concentrations may fall substantially during the overnight period, potentially leaving nighttime and early morning blood pressure less well controlled. This pharmacokinetic advantage, combined with its stronger outcome trial evidence base (ALLHAT, SHEP), is why chlorthalidone is the preferred thiazide-type diuretic.
Option A: Option A is incorrect because both drugs inhibit the same NCC transporter; chlorthalidone is structurally a thiazide-like agent rather than a true thiazide, but the transporter target is the same.
Option B: Option B is incorrect because both drugs are renally eliminated; hepatic metabolism is not the distinguishing pharmacokinetic feature.
Option C: Option C is incorrect because bioavailability differences between the agents are not the primary basis for clinical preference.
Option E: Option E is incorrect because chlorthalidone actually causes slightly more hypokalemia than HCTZ at equivalent antihypertensive doses, due to its longer duration of tubular action — metabolic safety is not the basis for its preference.
11. Loop diuretics inhibit the sodium-potassium-2-chloride cotransporter (NKCC2) in the thick ascending limb of the loop of Henle. Which of the following correctly distinguishes a loop diuretic adverse effect from a thiazide adverse effect at the level of calcium handling?
A) Loop diuretics increase urinary calcium excretion (calciuria) by abolishing the lumen-positive voltage in the thick ascending limb that normally drives paracellular calcium reabsorption; thiazides reduce urinary calcium excretion (hypocalciuria) by enhancing calcium reabsorption in the distal convoluted tubule — making these two diuretic classes opposites in their effect on urinary calcium
B) Both loop diuretics and thiazides reduce urinary calcium excretion; the difference is that loop diuretics act more potently at the same tubular site
C) Loop diuretics cause hypercalcemia by releasing calcium from bone; thiazides cause hypocalcemia by blocking intestinal calcium absorption
D) Loop diuretics cause hypocalciuria; thiazides cause calciuria — the opposite of what is commonly taught
E) Both loop diuretics and thiazides increase urinary calcium excretion; loop diuretics are simply more potent natriuretic agents at equivalent doses
ANSWER: A
Rationale:
The calcium handling effects of loop diuretics and thiazides are opposite and clinically important. In the thick ascending limb, NKCC2-driven sodium and potassium reabsorption creates a lumen-positive transepithelial voltage that drives paracellular reabsorption of calcium and magnesium. Loop diuretics abolish this voltage by blocking NKCC2, resulting in increased urinary calcium loss (calciuria). In the distal convoluted tubule, thiazide inhibition of NCC lowers intracellular sodium in tubular cells, enhancing the gradient for transcellular calcium reabsorption via TRPV5, resulting in reduced urinary calcium loss (hypocalciuria). These opposite effects have direct clinical applications: loop diuretics are used in hypercalcemia management (to promote calcium excretion); thiazides are used in calcium nephrolithiasis (to reduce calcium in the urine and limit stone formation).
Option B: Option B is incorrect because the two diuretic classes have opposite effects on urinary calcium, not the same effect at different potencies.
Option C: Option C is incorrect because neither diuretic class causes hypercalcemia from bone release or hypocalcemia from intestinal blockade.
Option D: Option D is incorrect because it states the relationship in reverse.
Option E: Option E is incorrect because thiazides reduce urinary calcium excretion, not increase it.
12. Spironolactone and amiloride are both classified as potassium-sparing diuretics, but they work by entirely different mechanisms. Which of the following correctly distinguishes them?
A) Spironolactone directly blocks epithelial sodium channels (ENaC) in the collecting duct independently of aldosterone; amiloride competitively antagonizes the mineralocorticoid receptor
B) Both agents block ENaC directly but at different sites — spironolactone at the luminal surface and amiloride at the basolateral membrane
C) Amiloride directly blocks ENaC at the luminal surface of collecting duct principal cells independently of aldosterone; spironolactone competitively antagonizes the mineralocorticoid receptor in the cytoplasm, reducing aldosterone-driven ENaC expression through a genomic mechanism requiring hours to manifest
D) Spironolactone is more potent than amiloride in all clinical situations because it acts upstream by blocking the signal that drives ENaC expression
E) Amiloride inhibits the Na+/K+-ATPase on the basolateral membrane of collecting duct cells; spironolactone blocks aldosterone synthesis in the adrenal gland
ANSWER: C
Rationale:
The mechanistic distinction between amiloride and spironolactone is fundamental and has direct clinical consequences. Amiloride physically occludes the ENaC pore at the luminal (apical) surface of collecting duct principal cells — an action that is entirely aldosterone-independent. This makes amiloride effective even when aldosterone levels are low or suppressed. The most important clinical implication is Liddle syndrome: a genetic disorder of constitutively active ENaC that causes severe hypertension with suppressed renin and aldosterone. In Liddle syndrome, amiloride is the drug of choice — it blocks the overactive channel directly — while spironolactone is ineffective because there is no aldosterone driving ENaC expression. Spironolactone works by antagonizing the mineralocorticoid receptor in the cytoplasm; without aldosterone binding, the receptor does not translocate to the nucleus and ENaC gene transcription falls — a genomic effect with a slow onset of hours. Option A has the mechanisms reversed.
Option B: Option B is incorrect because neither agent works at the basolateral membrane; amiloride acts at the apical (luminal) channel pore.
Option D: Option D is incorrect because spironolactone's clinical superiority depends on the presence of excess aldosterone; in aldosterone-independent states, amiloride is the effective agent.
Option E: Option E is incorrect because amiloride does not inhibit Na+/K+-ATPase and spironolactone does not suppress adrenal aldosterone synthesis.
13. A 64-year-old woman started on HCTZ 25 mg daily develops a serum potassium of 3.1 mEq/L at her four-week follow-up visit. Her physician considers adding a second agent that will both correct the hypokalemia and provide additional blood pressure control. Which of the following agents best serves both goals simultaneously through a single complementary mechanism?
A) Furosemide 20 mg daily — more potent natriuresis will correct the sodium imbalance causing the potassium shift
B) An ACE inhibitor or ARB — RAAS inhibition reduces angiotensin II, lowering aldosterone levels and thereby blunting the aldosterone-driven potassium secretion in the collecting duct that thiazides stimulate; these agents also provide substantial additional antihypertensive benefit
C) Amlodipine 5 mg daily — calcium channel blockade directly inhibits potassium secretion channels in the distal tubule
D) Propranolol 40 mg twice daily — beta-blockade reduces renin secretion and thereby reduces the aldosterone-mediated potassium wasting caused by thiazide-induced volume contraction
E) Verapamil 120 mg twice daily — non-DHP CCBs reduce glomerular filtration pressure, decreasing the sodium delivery to the collecting duct that drives potassium secretion
ANSWER: B
Rationale:
Thiazide diuretics cause hypokalemia through a two-step mechanism: natriuresis delivers increased sodium to the collecting duct, where aldosterone-mediated principal cell activation promotes potassium secretion in exchange for sodium reabsorption. RAAS inhibitors (ACE inhibitors or ARBs) reduce angiotensin II formation or action, which lowers aldosterone secretion from the adrenal cortex. With less aldosterone driving collecting duct sodium-potassium exchange, potassium wasting is blunted. This is both pharmacologically rational — complementary mechanisms that enhance each other's efficacy — and metabolically protective. The combination of a thiazide plus RAAS inhibitor is one of the most evidence-based antihypertensive combinations and directly addresses the hypokalemia mechanism.
Option A: Option A is incorrect because furosemide causes potassium wasting through the same downstream mechanism and would worsen hypokalemia significantly.
Option C: Option C is incorrect because amlodipine has no direct effect on renal tubular potassium handling; CCB action on vascular smooth muscle does not influence collecting duct potassium transport.
Option D: Option D is incorrect because while beta-blockers do reduce renin modestly, their effect on potassium correction is insufficient and indirect; beta-blockers also carry metabolic concerns in a patient already on a thiazide.
Option E: Option E is incorrect because verapamil has no clinically meaningful effect on renal tubular potassium handling.
14. The ACCOMPLISH trial compared two dual-drug antihypertensive combinations — benazepril plus amlodipine versus benazepril plus HCTZ — in high-risk hypertensive patients. The trial was stopped early. What was the primary finding and why did it matter?
A) Benazepril plus HCTZ was superior, demonstrating that diuretic-based combinations should always be preferred over CCB-based combinations in high-risk patients
B) Both combinations produced identical cardiovascular outcomes, confirming that any two complementary antihypertensive agents achieve equivalent protection if blood pressure targets are reached
C) Benazepril plus amlodipine was associated with significantly more peripheral edema and was stopped due to unacceptable tolerability in the CCB arm
D) Benazepril plus amlodipine was superior, reducing the primary composite cardiovascular endpoint by approximately 20% compared to benazepril plus HCTZ, despite similar achieved blood pressure in both groups — suggesting cardiovascular benefits beyond blood pressure lowering alone
E) Benazepril plus HCTZ caused severe hypokalemia in a significant proportion of patients, leading to early termination due to safety concerns
ANSWER: D
Rationale:
ACCOMPLISH enrolled approximately 11,500 high-risk hypertensive patients and was stopped early because of clear and statistically significant superiority of the benazepril plus amlodipine arm. The CCB-based combination reduced the primary composite endpoint (cardiovascular death, nonfatal MI, nonfatal stroke, hospitalization for angina, resuscitated arrest, or coronary revascularization) by approximately 20% relative risk reduction. Critically, both groups achieved virtually identical blood pressure reductions throughout the trial — meaning the outcome difference cannot be explained by superior blood pressure control in the CCB arm. This finding raised the hypothesis that amlodipine provides cardiovascular benefits beyond blood pressure lowering, possibly through antiatherosclerotic effects (supported by CAMELOT), superior 24-hour BP coverage, or more favorable effects on central aortic pressure. The result shifted clinical practice toward preferring the CCB plus RAAS inhibitor combination in high-risk patients.
Option A: Option A is incorrect — the diuretic arm was inferior, not superior.
Option B: Option B is incorrect — ACCOMPLISH demonstrated a clinically and statistically significant outcome difference.
Option C: Option C is incorrect — the trial was stopped for benefit in the CCB arm, not for tolerability concerns; peripheral edema occurred more in the CCB arm but was not the reason for stopping.
Option E: Option E is incorrect — hypokalemia was not the reason for early termination.
15. The PATHWAY-2 trial established a clear hierarchy among fourth-line antihypertensive agents in patients with resistant hypertension. Which of the following correctly describes what the trial found and why the winner pharmacologically makes sense?
A) Bisoprolol was superior because resistant hypertension is primarily driven by sympathetic overactivation, and beta-blockade addresses this root cause more directly than other agents
B) Doxazosin was superior because alpha-1 blockade reduces total peripheral resistance more potently than mineralocorticoid receptor antagonism in resistant hypertension
C) Amlodipine was superior because CCBs act through a renin-independent mechanism that is maximally effective when the RAAS is already fully blocked by the existing three-drug regimen
D) Chlorthalidone was superior because patients with resistant hypertension have breakthrough volume expansion that requires more aggressive natriuresis than standard thiazide doses provide
E) Spironolactone was superior to bisoprolol, doxazosin, and placebo, producing the greatest systolic blood pressure reduction of approximately 8.7 mmHg more than placebo — a result consistent with the observation that resistant hypertension in patients already on a diuretic, RAAS inhibitor, and CCB is often driven by relative aldosterone excess and volume-dependent physiology indicated by low plasma renin activity
ANSWER: E
Rationale:
PATHWAY-2 was a randomized, double-blind, crossover trial in patients with true resistant hypertension — BP above target on three optimized antihypertensive agents including a diuretic. Patients were randomized to spironolactone, bisoprolol, doxazosin, or placebo in crossover fashion. Spironolactone produced the largest systolic blood pressure reduction (~8.7 mmHg greater than placebo) and was significantly superior to bisoprolol and doxazosin. The benefit was greatest in patients with low plasma renin activity — consistent with the pathophysiological hypothesis that resistant hypertension, even without a formal diagnosis of primary aldosteronism, is often driven by relative mineralocorticoid excess and aldosterone-mediated volume expansion that escapes the renin suppression loop. Adding a mineralocorticoid receptor antagonist directly targets this mechanism.
Option A: Option A is incorrect because bisoprolol was inferior to spironolactone in PATHWAY-2, and high sympathetic tone is not the dominant mechanism in most cases of resistant hypertension.
Option B: Option B is incorrect because doxazosin was also inferior to spironolactone.
Option C: Option C is incorrect because PATHWAY-2 did not include an amlodipine arm; the enrolled patients were already on a CCB as one of their three drugs.
Option D: Option D is incorrect because chlorthalidone was not tested in PATHWAY-2; the enrolled patients were already on a diuretic.
16. A 69-year-old man with hypertension, permanent atrial fibrillation, and heart failure with reduced ejection fraction (HFrEF — meaning his heart's pumping function is reduced, with ejection fraction below 40%) is on carvedilol and lisinopril. His BP is 148/88 mmHg and his physician wants to add a CCB for additional blood pressure control. Which of the following correctly identifies the most important prescribing constraint in this patient?
A) Verapamil and diltiazem are contraindicated in HFrEF because their negative inotropic effect worsens outcomes in patients with already impaired cardiac function; amlodipine is the preferred CCB if one is needed, having been shown hemodynamically neutral in HFrEF in the V-HeFT III trial
B) Amlodipine is contraindicated in HFrEF because it causes reflex tachycardia that worsens atrial fibrillation rate control
C) All CCBs are equally contraindicated in HFrEF regardless of subclass; no CCB should be used in this patient under any circumstances
D) Diltiazem is safe in HFrEF while verapamil is contraindicated; the difference lies in diltiazem's lower negative inotropy at standard doses
E) The carvedilol must be discontinued before adding any CCB because all CCBs interact with beta-blockers to cause dangerous bradycardia
ANSWER: A
Rationale:
The CCB subclass distinction is clinically critical in HFrEF. Non-dihydropyridine CCBs — verapamil and diltiazem — have significant negative inotropic effects through cardiac L-type calcium channel blockade. In a patient whose contractility is already impaired by HFrEF, adding negative inotropy worsens cardiac function and has been associated with increased mortality. Both verapamil and diltiazem are contraindicated in HFrEF. Amlodipine, a dihydropyridine with high vascular selectivity and minimal direct cardiac effects, was specifically studied in HFrEF in the V-HeFT III trial and found to be hemodynamically neutral — neither worsening nor improving ejection fraction or survival. It can be used cautiously for blood pressure control when needed.
Option B: Option B is incorrect because amlodipine's minimal reflex tachycardia at standard doses is not the basis for any contraindication in HFrEF, and rate control in AF is addressed by carvedilol.
Option C: Option C is incorrect because amlodipine is not contraindicated in HFrEF.
Option D: Option D is incorrect because both verapamil and diltiazem are contraindicated in HFrEF; diltiazem is not selectively safer.
Option E: Option E is incorrect because combining carvedilol (a beta-blocker) with amlodipine (a DHP CCB) is safe; the dangerous beta-blocker plus CCB combination involves non-DHP CCBs specifically.
17. A 73-year-old woman with hypertension and a history of calcium oxalate kidney stones is being started on antihypertensive therapy. Her physician notes that one antihypertensive class has a paradoxical property that could benefit her stone history. Which class and mechanism is this?
A) Loop diuretics — they increase calcium excretion, washing out supersaturated calcium from the urine and preventing crystal nucleation
B) ACE inhibitors — they reduce glomerular filtration pressure and thereby reduce the filtered calcium load that drives stone formation
C) Thiazide and thiazide-like diuretics — NCC inhibition in the distal convoluted tubule lowers intracellular sodium in tubular cells, enhancing the gradient for passive calcium reabsorption via TRPV5 channels, resulting in hypocalciuria that reduces urinary calcium available for stone formation
D) Non-dihydropyridine CCBs — they block L-type calcium channels in the proximal tubule, reducing tubular calcium reabsorption and thereby lowering the calcium concentration in the tubular lumen where stones form
E) Potassium-sparing diuretics — amiloride blocks ENaC and thereby reduces sodium-calcium co-transport in the collecting duct, lowering urinary calcium
ANSWER: C
Rationale:
Thiazide and thiazide-like diuretics reduce urinary calcium excretion — a property that makes them specifically useful in patients with recurrent calcium nephrolithiasis. The mechanism begins with NCC inhibition in the DCT: less sodium enters tubular cells via NCC, lowering intracellular sodium. The reduced intracellular sodium concentration enhances the driving force for the basolateral Na+/Ca²⁺ exchanger to extrude calcium from the cell, which in turn draws more calcium into the cell from the tubular lumen via apical TRPV5 channels. Net calcium reabsorption in the DCT increases, and urinary calcium excretion falls. Lower urinary calcium reduces the supersaturation that drives calcium oxalate and calcium phosphate stone nucleation. This is a pharmacologically paradoxical but well-established and clinically exploited effect.
Option A: Option A is incorrect because loop diuretics increase calciuria — they would worsen calcium nephrolithiasis, not protect against it.
Option B: Option B is incorrect because ACE inhibitors do not have a specific calcium-handling effect on tubular reabsorption through this mechanism.
Option D: Option D is incorrect because non-DHP CCBs exert their effects on cardiac and vascular calcium channels, not on proximal tubular calcium transport.
Option E: Option E is incorrect because amiloride's ENaC blockade does not involve sodium-calcium co-transport in the collecting duct; its primary effect is on sodium and potassium handling.
18. A 66-year-old man with hypertension is on amlodipine 10 mg and losartan 100 mg daily with good blood pressure control but significant bilateral ankle edema. His BNP is normal. His physician wants to address the edema pharmacologically without switching or stopping the CCB. Based on the mechanism of CCB-associated edema established earlier in this question set, which intervention most directly targets the cause?
A) Add furosemide 20 mg daily — loop diuresis will reduce the sodium-driven volume overload causing the edema
B) Confirm losartan is at maximum dose (100 mg — already achieved here), then consider switching to a different RAAS inhibitor at maximum dose or adding a second RAAS inhibitor of a different class; RAAS inhibitor-induced venodilation and efferent arteriolar dilation reduce capillary hydrostatic pressure and directly counteract CCB-mediated edema — this is the pharmacological mechanism underlying ACCOMPLISH's superiority of the CCB plus RAAS inhibitor combination
C) Add metoprolol to reduce cardiac output and thereby lower the systemic capillary perfusion pressure causing the edema
D) Switch from losartan to chlorthalidone — diuretics directly address the fluid accumulation in the interstitium regardless of the mechanism that drove it there
E) Reduce the amlodipine dose to 2.5 mg and accept the trade-off of somewhat less blood pressure control in exchange for less edema
ANSWER: B
Rationale:
CCB-associated edema arises from preferential arteriolar dilation without matched venodilation, raising capillary hydrostatic pressure in dependent tissues. RAAS inhibitors counteract this specifically: by dilating efferent arterioles and venous capacitance vessels, they reduce the capillary hydrostatic pressure that arteriolar dilation created — directly addressing the hemodynamic mechanism rather than simply removing fluid after it has extravasated. This pharmacological rationale explains in part why the CCB plus RAAS inhibitor combination outperformed the CCB plus HCTZ combination in ACCOMPLISH: the RAAS inhibitor both adds antihypertensive efficacy and mitigates CCB edema. This patient is already on losartan 100 mg; since the maximum dose is already in use, the clinical options would be dose optimization of the CCB (dose reduction) or switching to felodipine (lower edema rate), while maintaining the RAAS inhibitor at maximum dose.
Option A: Option A is incorrect because furosemide targets sodium-mediated volume overload; CCB edema is a capillary hydrostatic pressure imbalance, not excess sodium, and loop diuretics have limited efficacy for this type of edema.
Option C: Option C is incorrect because reducing cardiac output with a beta-blocker does not selectively address the local capillary hydrostatic pressure imbalance at the arteriolar-venule level.
Option D: Option D is incorrect because switching the RAAS inhibitor to a diuretic removes the agent that most directly counteracts the CCB edema mechanism.
Option E: Option E is incorrect because reducing amlodipine to 2.5 mg would likely compromise blood pressure control significantly and is a dose-limitation strategy rather than a mechanistically targeted intervention.
19. A 68-year-old woman with hypertension secondary to confirmed bilateral adrenal hyperplasia causing primary aldosteronism (autonomous excess aldosterone production from both adrenal glands) is being managed medically rather than surgically. Which antihypertensive agent is the pharmacological treatment of choice and why?
A) Furosemide — loop diuresis overcomes the sodium retention that aldosterone drives, restoring normal blood pressure and potassium
B) Chlorthalidone — thiazides are the preferred diuretic in primary aldosteronism because they target the distal convoluted tubule where aldosterone acts
C) Lisinopril — ACE inhibition reduces angiotensin II, which is the primary stimulus for aldosterone production in primary aldosteronism
D) Amlodipine — CCBs are the most effective antihypertensive agents in low-renin states such as primary aldosteronism and directly address the volume-dependent component
E) Spironolactone — as a competitive mineralocorticoid receptor (MR) antagonist, it directly blocks the aldosterone receptor driving sodium retention, potassium wasting, and hypertension in bilateral adrenal hyperplasia, correcting all three pathophysiological abnormalities simultaneously
ANSWER: E
Rationale:
Primary aldosteronism with bilateral adrenal hyperplasia is treated medically with a mineralocorticoid receptor antagonist, with spironolactone as the drug of choice. Spironolactone competitively antagonizes aldosterone at the mineralocorticoid receptor in collecting duct principal cells, blocking the transcription of ENaC subunits and Na+/K+-ATPase — the molecular machinery through which aldosterone drives sodium retention and potassium secretion. By directly blocking the receptor mediating the disease pathophysiology, spironolactone corrects blood pressure, hypokalemia, and suppressed renin simultaneously. It targets the primary defect rather than compensating downstream.
Option A: Option A is incorrect because furosemide addresses volume but does not target the MR; it would worsen hypokalemia by increasing potassium excretion in the collecting duct.
Option B: Option B is incorrect because thiazides act upstream in the distal convoluted tubule and do not block the mineralocorticoid receptor; thiazides would also worsen hypokalemia.
Option C: Option C is incorrect because primary aldosteronism is autonomous — aldosterone is produced independently of angiotensin II. ACE inhibition reduces angiotensin II but does not suppress the autonomous adrenal aldosterone secretion.
Option D: Option D is incorrect because while CCBs are effective in low-renin states generally, they do not address the specific MR-mediated pathophysiology of primary aldosteronism and would not correct hypokalemia.
20. A 75-year-old woman with isolated systolic hypertension (ISH — systolic BP consistently above 160 mmHg with normal diastolic BP) is started on chlorthalidone 25 mg daily. Six weeks later she presents with confusion, nausea, and lethargy. Her serum sodium is 121 mEq/L. She weighs 51 kg, is small-framed, and drinks approximately 2 liters of water daily. Which of the following best explains why she developed severe hyponatremia while most patients on the same dose do not?
A) She has an underlying defect in ADH receptor sensitivity that was unmasked by chlorthalidone
B) Chlorthalidone directly stimulates hypothalamic ADH release in proportion to the dose administered; higher doses cause predictable ADH-driven hyponatremia
C) Chlorthalidone causes hyperaldosteronism as a compensatory response, which drives sodium into cells and reduces serum sodium without actual sodium loss
D) Her small body size means the same degree of natriuresis and free water retention produces a proportionally larger fall in serum sodium; volume contraction from natriuresis stimulates ADH release, impairing free water excretion; her high fluid intake further dilutes an already sodium-depleted extracellular compartment — all three factors acting simultaneously in a patient with small total body water volume
E) Chlorthalidone caused a Fanconi syndrome in this patient, producing tubular sodium wasting far in excess of what normal thiazide-mediated NCC inhibition causes
ANSWER: D
Rationale:
Thiazide-associated hyponatremia disproportionately affects elderly women with small body habitus who drink large volumes of fluid — precisely this patient's profile. The mechanism involves three simultaneous factors. First, natriuresis from NCC inhibition produces sodium loss. Second, the volume contraction stimulates ADH release from the posterior pituitary; ADH acts on the collecting duct to retain free water, which dilutes the remaining sodium. Third, thiazide-impaired ability to generate dilute urine (the kidney's mechanism for excreting free water) means the patient cannot excrete the 2 liters she drinks daily — it is retained and dilutes serum sodium further. Small body size amplifies all three effects: less total body water means any given sodium deficit or water excess produces a proportionally larger change in serum sodium concentration. The combination of these factors in a small elderly woman who drinks heavily can produce severe, symptomatic hyponatremia rapidly.
Option A: Option A is incorrect because underlying ADH receptor defects are not the mechanism; this is a pharmacodynamic susceptibility, not an idiosyncratic receptor abnormality.
Option B: Option B is incorrect because ADH stimulation is secondary to volume contraction, not a direct dose-proportional drug effect on the hypothalamus.
Option C: Option C is incorrect because hyperaldosteronism from thiazide-induced volume contraction causes sodium retention (raises sodium), not sodium entry into cells.
Option E: Option E is incorrect because Fanconi syndrome is a proximal tubular dysfunction not caused by thiazides.
21. A 58-year-old woman with hypertension and gout (three flares in two years; serum uric acid 8.6 mg/dL; on allopurinol) needs antihypertensive therapy. Her physician wants to choose a RAAS inhibitor that, among the available options, has a unique additional property beneficial for her gout. Which agent and property is this?
A) Losartan — uniquely among ARBs, it inhibits the URAT1 transporter (proximal tubular urate reabsorption transporter) in the proximal tubule, increasing urinary uric acid excretion and lowering serum uric acid; this uricosuric property is not shared by other ARBs or by ACE inhibitors
B) Lisinopril — ACE inhibitors reduce angiotensin II, which normally promotes proximal tubular urate reabsorption; ACE inhibition therefore lowers serum uric acid as a class effect
C) Valsartan — it is the most potent ARB at URAT1 inhibition and has the strongest uricosuric effect among all antihypertensive agents
D) Ramipril — its active metabolite ramiprilat directly inhibits xanthine oxidase in the liver, reducing uric acid synthesis in the same way as allopurinol
E) Irbesartan — it blocks uric acid reabsorption in the collecting duct via a mechanism independent of URAT1, providing a uricosuric effect without the proximal tubular transporter interaction
ANSWER: A
Rationale:
Losartan is the one ARB with a well-established, clinically meaningful uricosuric property — independent of and additive to its antihypertensive mechanism. Losartan and its active metabolite EXP3174 inhibit the URAT1 transporter in the proximal tubule, which is responsible for reabsorbing uric acid from the tubular lumen back into the bloodstream. By blocking this reabsorption, losartan increases urinary uric acid excretion and lowers serum uric acid levels. This property is unique to losartan among ARBs and is not a class effect. For a patient with hypertension and gout who needs a RAAS inhibitor, losartan is therefore the preferred choice — it addresses both clinical problems simultaneously.
Option B: Option B is incorrect because the class effect of ACE inhibitors does not include clinically meaningful uricosuric activity through angiotensin II reduction; ACE inhibitors do not lower uric acid as a class property.
Option C: Option C is incorrect because valsartan does not have significant URAT1 inhibition; the uricosuric property is specific to losartan.
Option D: Option D is incorrect because ramipril and its metabolites do not inhibit xanthine oxidase; xanthine oxidase inhibition is the mechanism of allopurinol and febuxostat.
Option E: Option E is incorrect because irbesartan does not have a clinically established uricosuric mechanism in the collecting duct.
22. A 62-year-old Black man with hypertension (BP 162/94 mmHg), no proteinuria, no diabetes, no heart failure, and no history of coronary artery disease is being started on antihypertensive therapy. His potassium is 4.5 mEq/L and eGFR is 68 mL/min/1.73m2. Applying the clinical principles from this module, which of the following initial strategies is most strongly supported by evidence and mechanistic rationale for this patient?
A) Lisinopril 10 mg daily — ACE inhibitors are the preferred first-line agent in all demographic groups regardless of comorbidity profile
B) Metoprolol succinate 50 mg daily — beta-blockers are highly effective in Black patients because low-renin hypertension responds well to cardiac output reduction
C) Amlodipine 5 mg daily or chlorthalidone 12.5 mg daily — both dihydropyridine CCBs and thiazide-type diuretics act through renin-independent mechanisms and are highly effective as initial therapy in Black patients, as supported by ALLHAT; either is an appropriate first choice with the selection guided by individual clinical factors
D) Verapamil 120 mg twice daily — non-DHP CCBs are preferred in Black patients because their cardiac rate-slowing effect reduces pulse pressure, which is the dominant hemodynamic abnormality in this demographic
E) Spironolactone 25 mg daily — mineralocorticoid receptor antagonism is the most physiologically targeted first-line agent in Black patients because low-renin hypertension is always caused by aldosterone excess
ANSWER: C
Rationale:
Black patients with hypertension typically have a low-renin, volume-expanded hemodynamic profile that makes them less responsive to RAAS inhibitors as monotherapy compared to other demographic groups — a pattern confirmed in ALLHAT, where lisinopril was inferior to chlorthalidone for stroke prevention in Black patients. By contrast, dihydropyridine CCBs and thiazide-type diuretics act through renin-independent mechanisms (vascular L-type calcium channel blockade and natriuresis/vascular adaptation, respectively) and are highly effective across demographic groups. ALLHAT demonstrated that amlodipine and chlorthalidone both provided excellent blood pressure control and cardiovascular event reduction in Black patients. Current ACC/AHA and JNC guidelines specifically recommend CCBs and thiazide-type diuretics as preferred first-line agents for Black patients without compelling indications for other classes.
Option A: Option A is incorrect because RAAS inhibitors as monotherapy are generally less effective in Black patients and ALLHAT showed lisinopril was inferior to chlorthalidone for stroke in this group.
Option B: Option B is incorrect because beta-blockers work best in high-renin states; low-renin hypertension in Black patients is not effectively treated by cardiac output reduction alone, and beta-blockers are not preferred first-line agents in this context.
Option D: Option D is incorrect because verapamil, a non-DHP CCB, is not preferred over the DHP CCBs in Black patients and carries risks of constipation, drug interactions, and cardiac conduction effects without additional benefit for uncomplicated hypertension.
Option E: Option E is incorrect because while volume-dependent low-renin hypertension does respond to MRAs, spironolactone is a fourth-line agent for resistant hypertension (PATHWAY-2), not a first-line agent; not all low-renin hypertension is caused by primary aldosteronism.
BEFORE YOU MOVE ON
You have just worked through 22 questions covering the full pharmacological landscape of calcium channel blockers and diuretics — two of the four cornerstone drug classes in hypertension management. The CCB questions asked you to distinguish dihydropyridines from non-dihydropyridines not as labels to memorize but as a clinical reasoning framework: tissue selectivity determines which patients benefit and which face serious harm. The diuretic questions took you from the basic NCC mechanism through to the paradoxical effects that make thiazides useful in nephrolithiasis, the mechanistic basis for hyponatremia risk, and the evidence base that places spironolactone at the top of the fourth-line hierarchy. These concepts — capillary hydrostatic pressure, URAT1 inhibition, the two-phase antihypertensive mechanism, the ACCOMPLISH finding — will appear in every tier above this one, applied to progressively more complex clinical scenarios.
You are now four modules into the hypertension series, which means the pharmacological toolkit is nearly complete. ACE inhibitors, ARBs, CCBs, diuretics, and the adjunctive agents from HTN-05 together cover the full treatment landscape that guideline-based practice draws from. The pattern that has been building across these modules — that drug selection in hypertension is determined by mechanism, comorbidity, and patient-specific physiology rather than by a single algorithm — is the insight Tier 1 will require you to apply with precision. The vocabulary you have built here is exactly the currency Tier 1 will spend.
Move forward when you are ready. The ground ahead is familiar.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.